← Back to Search

Procedure

Transcranial ExAblate for Trigeminal Neuralgia

N/A
Waitlist Available
Led By William J Elias, MD
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from pre-treatment through 3 months following treatment.
Awards & highlights

Study Summary

This trial is testing a new treatment for chronic pain caused by trigeminal nerve damage. The treatment is safe and feasible so far.

Eligible Conditions
  • Trigeminal Neuralgia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from pre-treatment through 3 months following treatment.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from pre-treatment through 3 months following treatment. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Numeric Pain Rating Scale (NPRS)
Severity of Device and Procedure Related Complications
Secondary outcome measures
Pain Interference Scale 8a v1.0 From the Patient-Reported Outcomes Measurement Information Systems (PROMIS) Pain Inventory

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Transcranial ExAblateExperimental Treatment1 Intervention
ExAblate Transcranial MR Guided Focused Ultrasound (MRgFUS)
Group II: Sham Transcranial ExAblatePlacebo Group2 Interventions
ExAblate MRgFUS Sham Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial ExAblate
2013
N/A
~80

Find a Location

Who is running the clinical trial?

InSightecLead Sponsor
88 Previous Clinical Trials
3,694 Total Patients Enrolled
1 Trials studying Trigeminal Neuralgia
10 Patients Enrolled for Trigeminal Neuralgia
William J Elias, MDPrincipal InvestigatorUniversity of Virginia
1 Previous Clinical Trials
4 Total Patients Enrolled

Media Library

Transcranial ExAblate (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03309813 — N/A
Trigeminal Neuralgia Research Study Groups: Sham Transcranial ExAblate, Transcranial ExAblate
Trigeminal Neuralgia Clinical Trial 2023: Transcranial ExAblate Highlights & Side Effects. Trial Name: NCT03309813 — N/A
Transcranial ExAblate (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03309813 — N/A
Trigeminal Neuralgia Patient Testimony for trial: Trial Name: NCT03309813 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Minnesota
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

After having covid my trigeminal pain increased to an unbearable level of pain. I need help.
PatientReceived no prior treatments
~1 spots leftby Apr 2025